Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group

PURPOSE: A phase I/II study of cixutumumab (IMC-A12) in children with refractory solid tumors was conducted. This study was designed to assess the toxicities, pharmacokinetics, and pharmacodynamics of cixutumumab in children to determine a recommended phase II dose and to assess antitumor activity i...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Malempati, Suman, Weigel, Brenda, Ingle, Ashish M., Ahern, Charlotte H., Carroll, Julie M., Roberts, Charles T., Reid, Joel M., Schmechel, Stephen, Voss, Stephan D., Cho, Steven Y., Chen, Helen X., Krailo, Mark D., Adamson, Peter C., Blaney, Susan M.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2012
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3269952/
https://ncbi.nlm.nih.gov/pubmed/22184397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.37.4355
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires